149 related articles for article (PubMed ID: 31079160)
1. Bottom-up physiologically-based biokinetic modelling as an alternative to animal testing.
Chan JCY; Tan SPF; Upton Z; Chan ECY
ALTEX; 2019; 36(4):597-612. PubMed ID: 31079160
[TBL] [Abstract][Full Text] [Related]
2. Predicting human tissue exposures to xenobiotics using a bottom-up physiologically-based biokinetic model.
Tan SPF; Chan ECY; Chan JCY
ALTEX; 2021; 38(2):253-268. PubMed ID: 33219385
[TBL] [Abstract][Full Text] [Related]
3. In Vitro-In Vivo Extrapolation of OATP1B-Mediated Drug-Drug Interactions in Cynomolgus Monkey.
Ufuk A; Kosa RE; Gao H; Bi YA; Modi S; Gates D; Rodrigues AD; Tremaine LM; Varma MVS; Houston JB; Galetin A
J Pharmacol Exp Ther; 2018 Jun; 365(3):688-699. PubMed ID: 29643253
[TBL] [Abstract][Full Text] [Related]
4. Proteomics-Informed Prediction of Rosuvastatin Plasma Profiles in Patients With a Wide Range of Body Weight.
Wegler C; Prieto Garcia L; Klinting S; Robertsen I; Wiśniewski JR; Hjelmesaeth J; Åsberg A; Jansson-Löfmark R; Andersson TB; Artursson P
Clin Pharmacol Ther; 2021 Mar; 109(3):762-771. PubMed ID: 32970864
[TBL] [Abstract][Full Text] [Related]
5. Extrapolation of the Hepatic Clearance of Drugs in the Absence of Albumin In Vitro to That in the Presence of Albumin In Vivo: Comparative Assessement of 2 Extrapolation Models Based on the Albumin-Mediated Hepatic Uptake Theory and Limitations and Mechanistic Insights.
Poulin P; Haddad S
J Pharm Sci; 2018 Jul; 107(7):1791-1797. PubMed ID: 29567347
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic Modeling of Pitavastatin Disposition in Sandwich-Cultured Human Hepatocytes: A Proteomics-Informed Bottom-Up Approach.
Vildhede A; Mateus A; Khan EK; Lai Y; Karlgren M; Artursson P; Kjellsson MC
Drug Metab Dispos; 2016 Apr; 44(4):505-16. PubMed ID: 26842596
[TBL] [Abstract][Full Text] [Related]
7. Development of a Combined In Vitro Physiologically Based Kinetic (PBK) and Monte Carlo Modelling Approach to Predict Interindividual Human Variation in Phenol-Induced Developmental Toxicity.
Strikwold M; Spenkelink B; Woutersen RA; Rietjens IMCM; Punt A
Toxicol Sci; 2017 Jun; 157(2):365-376. PubMed ID: 28498972
[TBL] [Abstract][Full Text] [Related]
8. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R; Martin P; Surry D; Sharma P; Fenner K
Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
[TBL] [Abstract][Full Text] [Related]
9. Prediction and Quantification of Hepatic Transporter-Mediated Uptake of Pitavastatin Utilizing a Combination of the Relative Activity Factor Approach and Mechanistic Modeling.
Mitra P; Weinheimer S; Michalewicz M; Taub ME
Drug Metab Dispos; 2018 Jul; 46(7):953-963. PubMed ID: 29666154
[TBL] [Abstract][Full Text] [Related]
10. Quantitative assessment of the contribution of sodium-dependent taurocholate co-transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin.
Bi YA; Qiu X; Rotter CJ; Kimoto E; Piotrowski M; Varma MV; Ei-Kattan AF; Lai Y
Biopharm Drug Dispos; 2013 Nov; 34(8):452-61. PubMed ID: 23996477
[TBL] [Abstract][Full Text] [Related]
11. Effects of rosuvastatin and pitavastatin on ischemia-induced myocardial stunning in dogs.
Satoh K; Takaguri A; Itagaki M; Kano S; Ichihara K
J Pharmacol Sci; 2008 Apr; 106(4):593-9. PubMed ID: 18403900
[TBL] [Abstract][Full Text] [Related]
12. Intestinal in vitro transport assay combined with physiologically based kinetic modeling as a tool to predict bile acid levels in vivo.
De Bruijn VMP; Te Kronnie W; Rietjens IMCM; Bouwmeester H
ALTEX; 2024 Jan; 41(1):20-36. PubMed ID: 37528756
[TBL] [Abstract][Full Text] [Related]
13. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
[TBL] [Abstract][Full Text] [Related]
14. Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans.
Watanabe T; Kusuhara H; Maeda K; Kanamaru H; Saito Y; Hu Z; Sugiyama Y
Drug Metab Dispos; 2010 Feb; 38(2):215-22. PubMed ID: 19875501
[TBL] [Abstract][Full Text] [Related]
15. Integrating in vitro data and physiologically based kinetic (PBK) modelling to assess the in vivo potential developmental toxicity of a series of phenols.
Strikwold M; Spenkelink B; de Haan LHJ; Woutersen RA; Punt A; Rietjens IMCM
Arch Toxicol; 2017 May; 91(5):2119-2133. PubMed ID: 27815601
[TBL] [Abstract][Full Text] [Related]
16. Application of the extended clearance concept classification system (ECCCS) to predict the victim drug-drug interaction potential of statins.
Kunze A; Poller B; Huwyler J; Camenisch G
Drug Metab Pers Ther; 2015 Sep; 30(3):175-88. PubMed ID: 25996489
[TBL] [Abstract][Full Text] [Related]
17. Impact of in vitro experimental variation in kinetic parameters on physiologically based kinetic (PBK) model simulations.
Punt A; Bos P; Hakkert B; Louisse J
ALTEX; 2023; 40(2):237–247. PubMed ID: 35901496
[TBL] [Abstract][Full Text] [Related]
18. Prediction of Drug Clearance from Enzyme and Transporter Kinetics.
Kulkarni PR; Youssef AS; Argikar AA
Methods Mol Biol; 2021; 2342():369-417. PubMed ID: 34272702
[TBL] [Abstract][Full Text] [Related]
19. Successful Prediction of In Vivo Hepatobiliary Clearances and Hepatic Concentrations of Rosuvastatin Using Sandwich-Cultured Rat Hepatocytes, Transporter-Expressing Cell Lines, and Quantitative Proteomics.
Ishida K; Ullah M; Tóth B; Juhasz V; Unadkat JD
Drug Metab Dispos; 2018 Jan; 46(1):66-74. PubMed ID: 29084782
[TBL] [Abstract][Full Text] [Related]
20. Use of in vitro data in developing a physiologically based pharmacokinetic model: Carbaryl as a case study.
Yoon M; Kedderis GL; Yan GZ; Clewell HJ
Toxicology; 2015 Jun; 332():52-66. PubMed ID: 24863738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
